Plant-Based Vaccines: Principle, Production Methods, Applications, Advantages, Limitations & Clinical Trials

Table of Contents

• Introduction to Plant-Based Vaccines
• What are Plant-Based Vaccines?
• History of Plant-Based Vaccines
• Principle of Plant-Based Vaccines
• Production of Plant-Based Vaccines
• Methods for Production of Plant-Based Vaccines
• Applications of Plant-Based Vaccines
• Advantages of Plant-Based Vaccines
• Limitations of Plant-Based Vaccines
• Plant-based vaccines in clinical trials phase
• Conclusion
• References

Introduction to Plant-Based Vaccines

• Vaccines are biological preparations that stimulate or train the immune system to recognize and protect the body against specific infectious diseases, even if the individual has never been exposed to the pathogen before.
• The production of conventional vaccines is a complex process that requires advanced manufacturing facilities, strict quality control, significant financial investment, and an efficient distribution system.
• Vaccine manufacturing and delivery can be particularly challenging in underdeveloped and developing countries due to high production costs, cold-chain storage requirements, and limited healthcare infrastructure.
• Plant-based vaccines, especially edible plant vaccines, have emerged as a promising alternative to conventional vaccines.
• Compared with traditional vaccines, plant-based vaccines are generally more cost-effective, easier to produce, and simpler to administer, reducing the need for trained healthcare personnel.
• Edible plant-based vaccines also offer better temperature stability, minimizing dependence on cold-chain transportation and storage, making them especially suitable for resource-limited settings.

What are Plant-Based Vaccines?

• Plant-based vaccines are recombinant protein subunit vaccines in which vaccine antigens are produced using genetically engineered plants instead of conventional production systems.
• These vaccines work by expressing a specific antigenic protein of a pathogen in plant tissues. When administered, the antigen stimulates the human immune system to produce a protective immune response against the target disease.
• Compared with conventional vaccines, plant-based vaccines are generally more cost-effective, scalable, and efficient to produce, making them an attractive alternative for large-scale vaccine manufacturing.

History of Plant-Based Vaccines

• The concept of producing vaccines in plants was first explored in 1989, when Hiatt and colleagues demonstrated the potential of plants as platforms for producing recombinant proteins.
• Later, Dr. Charles J. Arntzen and his research team introduced the idea of using transgenic plants for vaccine production and successfully developed one of the first plant-based vaccine candidates in tobacco plants.
• Since then, significant advances have been made in plant molecular farming, with more than 200 recombinant proteins successfully produced in various plant species.
• These developments highlight the growing potential of plant-based vaccines as a safe, economical, and sustainable platform for future vaccine production.

Principle of Plant-Based Vaccines

• Plant-based vaccines are produced by introducing the gene of interest (encoding a target antigen) into a suitable expression vector, such as a bacterium (e.g., Agrobacterium tumefaciens) or a plant virus.
• The vector transfers the target gene into plant cells, where it is integrated or transiently expressed.
• The genetically modified plant cells synthesize the antigenic protein of the target pathogen.
• The expressed antigen is then harvested, purified, and processed to produce a vaccine formulation. In some cases, edible plant tissues containing the antigen may also be used directly.
• When administered to humans or animals, the antigen is recognized by the immune system, triggering the production of specific antibodies and immune cells.
• This immune response provides protective immunity, enabling the body to recognize and respond more effectively if exposed to the actual pathogen in the future.

Production of Plant-Based Vaccines

The production of plant-based vaccines involves introducing a transgene (an artificially engineered gene encoding the desired antigen) into plant cells, enabling the plants to produce vaccine proteins.

Steps in Production

• A gene of interest encoding the target antigen is first identified and isolated.
• The gene is inserted into a suitable expression vector, commonly Agrobacterium tumefaciens or a plant viral vector.
• The vector is introduced into plant cells, transferring the transgene into the plant.
• The transformed plant cells express the antigenic protein encoded by the transgene.
• The antigen is then harvested, purified, and formulated into a vaccine. In some cases, edible plant tissues containing the antigen may be used directly.

Types of Plant Transformation

1. Stable Transformation

• Stable transformation involves the permanent integration of the transgene into the plant genome.
• The inserted gene is inherited by subsequent generations of plants.
• It can occur through nuclear transformation or chloroplast (plastid) transformation.
• This method is suitable for long-term and large-scale vaccine production.

2. Transient Transformation

• Transient transformation involves temporary expression of the transgene without integrating it into the plant genome.
• The introduced gene remains active only for a short period.
• Whole-plant regeneration is not required, making the process faster than stable transformation.
• It typically produces higher levels of recombinant protein within a short time, making it ideal for rapid vaccine production during outbreaks.

Methods for Production of Plant-Based Vaccines

Plant-based vaccines are produced by introducing the desired antigen gene into plant cells using direct or indirect gene delivery methods. Each method differs in its mechanism, efficiency, cost, and applications.

1. Direct Gene Delivery Method

• The direct gene delivery method involves the physical introduction of genetic material directly into plant cells or tissues without the use of a biological vector.
• It enables rapid and targeted delivery of DNA into plant cells.
• Common direct delivery methods include:
• Biolistic (Gene Gun) Method
• Chloroplast Transformation

A. Biolistic Method (Gene Gun Method)

• Also known as the microprojectile bombardment method or gene gun method.
• It is a vector-independent technique in which DNA is delivered directly into plant cells.
• The desired DNA is coated onto microscopic gold or tungsten particles.
• These particles are accelerated at high velocity using a gene gun and shot into plant tissues.
• Once inside the cells, the DNA is released and expressed by the plant.

Advantages:

• Does not require a biological vector.
• Can transform a wide range of plant species.
• Suitable for both nuclear and chloroplast transformation.

Limitations:

• Requires expensive equipment.
• May cause physical damage to plant tissues.
• Transformation efficiency can vary.

2. Indirect Gene Delivery Method

• The indirect gene delivery method uses a biological vector, most commonly Agrobacterium tumefaciens, to transfer the desired gene into plant cells.
• It is one of the most efficient and widely used methods for producing transgenic plants and plant-based vaccines.

A. Agrobacterium-Mediated Gene Transfer

• Agrobacterium tumefaciens is a Gram-negative soil bacterium naturally associated with crown gall disease in plants.
• Due to its natural ability to transfer DNA into plant cells, it is often referred to as "nature's genetic engineer."
• The bacterium transfers a DNA segment called Transfer DNA (T-DNA) from its Ti (tumor-inducing) plasmid into the plant genome.
• For vaccine production, the Ti plasmid is genetically modified by replacing disease-causing genes with the desired antigen gene.
• The engineered Agrobacterium infects plant cells and transfers the antigen gene.
• The transformed plant cells then express the recombinant antigen, which can be harvested for vaccine production.

Advantages:

• High transformation efficiency.
• Relatively inexpensive.
• Causes minimal damage to plant tissues.
• Suitable for large-scale vaccine production.

B. Agroinfiltration

• Agroinfiltration is a technique used for transient gene expression in plants.
• Instead of permanently integrating the gene into the plant genome, the introduced gene is expressed temporarily.
• The process is performed by:
• Syringe agroinfiltration, where a bacterial suspension is injected into leaves using a syringe.
• Vacuum infiltration, where plant tissues are submerged in an infiltration buffer and exposed to a vacuum, allowing bacterial entry.
• Syringe agroinfiltration is simpler, faster, and more economical than vacuum infiltration.
• This method is widely used for rapid production of recombinant proteins and vaccines.

C. Chloroplast Transformation

• Chloroplast transformation involves introducing the desired antigen gene into the chloroplast genome instead of the nuclear genome.
• Gene delivery can be achieved using direct methods (gene gun) or indirect transformation techniques.
• Chloroplasts contain multiple copies of their own genome, resulting in high levels of recombinant protein expression.
• Since chloroplast DNA is generally maternally inherited in most plant species, the risk of transgene spread through pollen is greatly reduced.

Advantages:

• High protein expression due to multiple chloroplast genome copies.
• Reduced risk of transgene escape through pollen.
• Lower production costs.
• Rapid and efficient large-scale vaccine production.
• Stable expression of recombinant proteins.

Applications of Plant-Based Vaccines

• Prevention of Infectious Diseases: Plant-based vaccines are used to produce antigens and virus-like particles (VLPs) for protecting against infectious diseases such as COVID-19, influenza, norovirus, hepatitis B, and rabies. Plants like Nicotiana benthamiana are widely used as expression systems.
• Veterinary Medicine: Plant-derived vaccines help protect livestock, poultry, and companion animals against infectious diseases. Examples include vaccines for Newcastle disease in poultry and foot-and-mouth disease in cattle.
• Needle-Free Vaccine Delivery: Edible plant vaccines offer the potential for oral immunization, eliminating the need for injections. Plants such as banana, potato, tomato, rice, and lettuce can be engineered to express vaccine antigens that stimulate mucosal and systemic immune responses.
• Autoimmune Disease Management: Plant-produced autoantigens can be administered orally to induce immune tolerance, offering a potential therapeutic approach for autoimmune diseases such as type 1 diabetes and multiple sclerosis.
• Cancer Immunotherapy: Plant expression systems are being explored for the production of personalized cancer vaccines and tumor-associated antigens to stimulate targeted anti-cancer immune responses.
• Production of Recombinant Biopharmaceuticals: Plants are widely used to produce recombinant vaccine antigens, virus-like particles (VLPs), monoclonal antibodies, and other therapeutic proteins for human and veterinary medicine.
• Rapid Response to Disease Outbreaks: Plant-based platforms enable the fast production of vaccines during emerging infectious disease outbreaks and pandemics, reducing the time required for vaccine development.
• Development of Multivalent Vaccines: Plants can produce vaccines containing multiple antigens, allowing protection against two or more pathogens with a single vaccine formulation.
• Vaccines Against Emerging and Neglected Diseases: Plant-based technology is being investigated for the development of next-generation vaccines against neglected tropical diseases, emerging viral infections, and antimicrobial-resistant (AMR) pathogens.
• Affordable Vaccine Production: Due to their relatively low production costs and reduced cold-chain requirements, plant-based vaccines are particularly suitable for low- and middle-income countries, improving global access to vaccination.

Advantages of Plant-Based Vaccines

• Lower Manufacturing Costs: Plant-based vaccines are considerably less expensive to produce than conventional vaccines. Plants are easy to cultivate on a large scale and require fewer specialized facilities, costly reagents, and complex manufacturing processes.
• Reduced Dependence on Cold-Chain Storage: Many plant-based vaccines exhibit improved stability and may require less stringent refrigeration than conventional vaccines. This reduces reliance on cold-chain transportation and storage, making distribution easier, particularly in remote and resource-limited regions.
• Easy and Needle-Free Administration: Many plant-based vaccines are being developed as oral (edible) vaccines, eliminating the need for injections. This improves patient compliance, reduces the need for trained healthcare personnel, and minimizes the risk of needle-associated injuries and infections.
• Proper Protein Folding and Post-Translational Modifications: Plants can perform post-translational modifications, protein folding, and protein assembly similar to those in animal cells. These processes are essential for producing biologically active and highly immunogenic vaccine proteins.
• Environmentally Friendly Production: Plant-based vaccine production is considered environmentally sustainable because plants utilize sunlight, water, and carbon dioxide (CO₂) for growth. The process also requires fewer chemicals and generates less environmental waste than many conventional production systems.
• Scalable and Rapid Production: Plants can be cultivated quickly on a large scale, enabling rapid production of vaccine antigens during epidemics and pandemics.
• Low Risk of Human Pathogen Contamination: Unlike animal cell cultures, plants do not harbor human pathogens, reducing the risk of contamination with human viruses or prions and improving the overall safety of vaccine production.
• Therapeutic Applications: In addition to preventive vaccines, plant expression systems can produce therapeutic proteins and enzymes. A notable example is taliglucerase alfa, a recombinant enzyme produced in carrot cells that was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of Gaucher disease, demonstrating the clinical potential of plant-based biopharmaceuticals.

Limitations of Plant-Based Vaccines

• Potential Allergenic and Immunogenic Concerns: Plant-based vaccines, particularly edible vaccines, may trigger allergic reactions in susceptible individuals. In addition, differences in post-translational modifications, especially glycosylation patterns, may alter antigen structure and affect vaccine immunogenicity.
• Cost of Downstream Processing: Although plant cultivation is relatively inexpensive, the extraction, purification, quality control, and formulation of recombinant vaccine proteins require specialized infrastructure, increasing overall production costs.
• Biosafety and Environmental Risks: There is a potential risk of transgenic plants escaping into the environment through accidental release or cross-pollination. These plants may also be unintentionally consumed by humans or animals, making strict biosafety and containment measures essential.
• Challenges in Host Plant Selection: Selecting the most suitable plant expression system and target antigen can be difficult, as not all plant species efficiently express every recombinant protein or vaccine antigen.
• Variation in Antigen Expression: The level of antigen production can vary between individual plants and even among different tissues of the same plant. This variability makes it challenging to achieve consistent vaccine dosage and potency, particularly for edible vaccines.
• Regulatory and GMP Compliance: Manufacturing plant-based vaccines under Good Manufacturing Practice (GMP) standards can be challenging. It requires controlled production facilities, sterile processing conditions, rigorous quality assurance, and, in many cases, enclosed greenhouses or specialized cultivation systems.
• Limited Number of Licensed Products: Despite promising research and clinical trials, only a limited number of plant-based vaccines and plant-derived biopharmaceuticals have received regulatory approval, indicating that the technology is still developing.
• Public Acceptance and Regulatory Challenges: The use of genetically modified (transgenic) plants for vaccine production may raise public concerns and regulatory hurdles, potentially affecting commercialization and widespread adoption.

Plant-based vaccines in clinical trials phase

Host	Target Disease/Pathogen	Antigen	Plant	Expression System	Administration Route
Human	Norovirus	Capsid protein	Potato	Transgenic	Oral
Human	Hepatitis B virus (HBV)	Major surface protein (HBsAg)	Lettuce	Transgenic	Oral
Human	Influenza A (H5N1)	Hemagglutinin (HA)	Nicotiana benthamiana	Transient (Launch Vector)	Intramuscular
Human	Cholera	Cholera toxin B subunit (CTB)	Rice	Transgenic	Oral
Chicken	Newcastle Disease	Hemagglutinin-Neuraminidase (HN)	Tobacco suspension cells	Transgenic	Subcutaneous
Pig	Enterotoxigenic Escherichia coli (ETEC)	F4 fimbriae	Tobacco	Chloroplast transformation	Oral

Conclusion

• Plant-based vaccines represent a promising and innovative alternative to conventional vaccine production systems.
• They offer several advantages, including lower production costs, improved scalability, reduced dependence on cold-chain storage, and the potential for needle-free oral administration.
• These benefits make plant-based vaccines particularly valuable for developing and low-resource countries, where conventional vaccine production and distribution can be expensive and challenging.
• Despite their potential, concerns such as biosafety, transgene containment, regulatory compliance, and consistent antigen expression must be carefully addressed.
• Continued research and technological advancements are essential to improve the safety, efficacy, large-scale production, and commercial adoption of plant-based vaccines.
• With ongoing innovation, plant-based vaccines have the potential to play a significant role in the future of global immunization and public health.

References

• Biolistic Transformation—An Overview. (n.d.). ScienceDirect Topics. Retrieved May 11, 2025, from https://www.sciencedirect.com/topics/immunology-and-microbiology/biolistic-transformation
• Demirer, G. S., & Landry, M. P. (2017). Traditional methods of gene delivery to plants are labor- and time-intensive, suitable for only a limited number of host species, and often exhibit high toxicity and limited practical applicability. This work discusses the potential of nanoparticle-based approaches for efficient gene delivery in plants.
• Jamiepighin. (2006, August 20). Transgenic Crops: How Genetics Is Providing New Ways to Envision Agriculture. Science Creative Quarterly (SCQ). https://www.scq.ubc.ca/transgenic-crops-how-genetics-is-providing-new-ways-to-envision-agriculture/
• Kumar, A. U., & Ling, A. P. K. (2021). Gene introduction approaches in chloroplast transformation and their applications. Journal of Genetic Engineering & Biotechnology, 19, 148. https://doi.org/10.1186/s43141-021-00255-7
• Plant-Based Vaccine Design Services. (n.d.). Creative Biolabs. Retrieved May 11, 2025, from https://www.creative-biolabs.com/vaccine/plant-based-vaccines.htm
• Plant-Based COVID-19 Vaccine Enters Phase I Trials. (n.d.). European Pharmaceutical Review. Retrieved May 11, 2025, from https://www.europeanpharmaceuticalreview.com/news/124092/plant-based-covid-19-vaccine-enters-phase-i-trials/
• Rosales-Mendoza, S., Nieto-Gómez, R., & Angulo, C. (2017). A perspective on the development of plant-made vaccines in the fight against Ebola virus. Frontiers in Immunology, 8, 252. https://doi.org/10.3389/fimmu.2017.00252
• Sala, F., Rigano, M. M., Barbante, A., Basso, B., Walmsley, A. M., & Castiglione, S. (2003). Vaccine antigen production in transgenic plants: Strategies, gene constructs, and perspectives. Vaccine, 21(7), 803–808. https://doi.org/10.1016/S0264-410X(02)00603-5
• Takeyama, N., Kiyono, H., & Yuki, Y. (2015). Plant-based vaccines for animals and humans: Recent advances in technology and clinical trials. Therapeutic Advances in Vaccines, 3(5–6), 139–154. https://doi.org/10.1177/2051013615613272